hi reon1, can you be more specific on the other ASX companies that are targeting AML? For example, are you referring to RAC?
RAC’s phase 1B/2 results look promising. However, it is important to note that only 40% of the patients responded to the treatment and that five of the six responders died due to later complications with stem cell or related follow up treatments. So patients weren’t really cured even tho 5/6 responders had CRs.
conclusion: CHMs results are superior to RAC (albeit with a smaller sample). RAC market cap is $288 mill versus CHM $12m.
CHM Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)